Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 180 Bullish Setup | Bullish Swing Setup | -4.86% | |
| NR7 | Range Contraction | -4.86% | |
| NR7-2 | Range Contraction | -4.86% | |
| Narrow Range Bar | Range Contraction | -4.86% | |
| NR7 | Range Contraction | -4.08% | |
| Narrow Range Bar | Range Contraction | -4.08% | |
| Inside Day | Range Contraction | -4.08% | |
| 20 DMA Resistance | Bearish | -6.37% |
| Alert | Time |
|---|---|
| Possible NR7 | 1 day ago |
| 10 DMA Support | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Fell Below 10 DMA | 2 days ago |
| Possible NR7 | 3 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.28 |
| 52 Week Low | 2.2 |
| Average Volume | 15,811 |
| 200-Day Moving Average | 3.99 |
| 50-Day Moving Average | 4.80 |
| 20-Day Moving Average | 5.05 |
| 10-Day Moving Average | 4.89 |
| Average True Range | 0.46 |
| RSI (14) | 44.13 |
| ADX | 16.65 |
| +DI | 14.26 |
| -DI | 20.50 |
| Chandelier Exit (Long, 3 ATRs) | 4.25 |
| Chandelier Exit (Short, 3 ATRs) | 5.83 |
| Upper Bollinger Bands | 5.53 |
| Lower Bollinger Band | 4.57 |
| Percent B (%b) | 0.14 |
| BandWidth | 19.06 |
| MACD Line | -0.05 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0482 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.47 | ||||
| Resistance 3 (R3) | 5.46 | 5.21 | 5.34 | ||
| Resistance 2 (R2) | 5.21 | 5.01 | 5.21 | 5.29 | |
| Resistance 1 (R1) | 4.95 | 4.89 | 4.83 | 4.96 | 5.25 |
| Pivot Point | 4.70 | 4.70 | 4.63 | 4.70 | 4.70 |
| Support 1 (S1) | 4.44 | 4.50 | 4.32 | 4.45 | 4.15 |
| Support 2 (S2) | 4.19 | 4.38 | 4.19 | 4.11 | |
| Support 3 (S3) | 3.93 | 4.19 | 4.06 | ||
| Support 4 (S4) | 3.94 |
